Medscape is available in 5 Language Editions – Choose your Edition here.


Degos Disease Treatment & Management

  • Author: Noah S Scheinfeld, JD, MD, FAAD; Chief Editor: Dirk M Elston, MD  more...
Updated: Jan 25, 2016

Medical Care

Until 2010, no medical therapy for Degos disease (DD) was noted to be uniformly effective. Antiplatelet drugs (eg, aspirin, dipyridamole) may reduce the number of new lesions in some patients with only skin involvement. Some believe intravenous immunoglobulin may have a role in treatment.[40] This has changed with the reports that eculizumab can effectively treat systemic Degos disease.[1]

The initial enthusiasm for eculizumab as monotherapy may have faded. Burgin et al note that eculizumab (900 mg/d) failed as treatment for advanced systemic atrophic papulosis with GI involvement, with fatality as the outcome.[41] Shapiro et al note that only two patients initially given eculizumab as monotherapy are still alive; they instead use a combination of subcutaneous treprostinil and eculizumab.[42] Eculizumab, if given early enough, may help abate malignant atrophic papulosis, but as monotherapy it is not instrumental in controlling it.  With four patients treated, there have had no deaths. The first two are now six-year survivors. Each of them had been critically ill in ICU settings prior to therapy. This information is important because malignant atrophic papulosis without treatment or hope of treatment is lethal and patients should be directed towards those experienced with treatment as eculizumab alone may not work.

Other reports[43] have supported the use of eculizumab for systemic Degos disease but informal communication to the author noted that despite treatment with eculizumab, some patients with systemic Degos disease have died. One report noted 2 patients with Degos disease in whom eculizumab failed.[44] One had overlapping lupus and the other had pulmonary hypertension. The pulmonary hypertension patient was treated with treprostinil and cutaneous MAP lesions resolved but disabling digital pain manifested. In the patient with Degos disease and lupus, treprostinil temporally resulted in clearing of hematuria, CNS symptoms and MRI finding improvements.

A presentation by Magro et al[45] reported that eculizumab, which has been approved for paroxysmal nocturnal hemoglobinuria, improved systemic Degos disease in 3 patients. This small series was uncontrolled, but the results suggest promise for eculizumab as a treatment. The effectiveness of eculizumab also may support the idea that Degos disease is not a collagen-vascular disease, but instead is an endothelial- or complement-mediated disease. Eculizumab is expensive, which may hinder its acceptance as widely used therapy.

An article published in 2013 found that exploratory treatment with eculizumab did not help the development or progression of Degos disease systemic manifestations,[46] with 5 of 7 patients’ disease initially improving but then regressing, with progression of disease in 1 immediately and the 4 others after a period of time.

A proposed new treatment for Degos disease is treprostinil, a medication for pulmonary hypertension. Shapiro et al (2013) report a series of 3 patients treated with subcutaneous treprostinil (dose not reported).[47] One patient had systemic lupus erythematosus (SLE), overlap scleroderma, extensive malignant atrophic papulosis lesions, and severe pulmonary hypertension without CNS or bowel involvement. She was placed on therapy with treprostinil for her pulmonary hypertension, but in the months subsequent to initiation of treatment, dramatic and complete resolution of cutaneous malignant atrophic papulosis–like lesions and disabling digital pain occurred. The second patient had pure malignant atrophic papulosis but progressive organ (CNS, bladder, neurological, and gross hematuria) dysfunction despite eculizumab treatment, but therapy with treprostinil was temporally associated with clearing of hematuria, resolution of CNS symptoms, and improvement in MRI findings.

Other treatments that have been tried without real effect include the following: topical corticosteroids, phenformin and ethylestrenol, iodohydroxyquinoline, aspirin and dipyridamole, phenylbutazone, arsenic, sulfonamides, dextran, corticosteroids, heparin, warfarin, niacin, streptomycin, corticotropin, azathioprine, methotrexate, cyclosporine, tacrolimus, mycophenolate mofetil, pentoxifylline, and clopidogrel.

Hohwy et al[35] treated a patient with fatal systemic malignant atrophic papulosis (MAP) with narrow-band ultraviolet (UVB) light and prednisolone and, later, with aspirin, pentoxifylline, and warfarin. Treatment was not effective. Interestingly, the patient has a mutation of factor V Leiden and lupus anticoagulant.


Surgical Care

When gastrointestinal bleeding, intestinal perforation, bowel infarction, or intracranial bleeding occurs, proper surgical intervention is necessary.



Consult the following physicians:

  • Dermatologists
  • Gastroenterologists
  • Neurologists
  • General surgeons
  • Neurosurgeons
  • Ophthalmologists


Patients are often weak and this limits their activity, but no limitation to Degos disease itself exists.

Contributor Information and Disclosures

Noah S Scheinfeld, JD, MD, FAAD Assistant Clinical Professor, Department of Dermatology, Weil Cornell Medical College; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Assistant Attending Dermatologist, New York Presbyterian Hospital; Assistant Attending Dermatologist, Lenox Hill Hospital, North Shore-LIJ Health System; Private Practice

Noah S Scheinfeld, JD, MD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Abbvie<br/>Received income in an amount equal to or greater than $250 from: Optigenex<br/>Received salary from Optigenex for employment.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Jeffrey J Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Society for Investigative Dermatology, Association of Professors of Dermatology, North American Hair Research Society

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Franklin Flowers, MD Department of Dermatology, Professor Emeritus Affiliate Associate Professor of Pathology, University of Florida College of Medicine

Franklin Flowers, MD is a member of the following medical societies: American College of Mohs Surgery

Disclosure: Nothing to disclose.

  1. Magro CM, Poe JC, Kim C, Shapiro L, Nuovo G, Crow MK, et al. Degos disease: a C5b-9/interferon-a-mediated endotheliopathy syndrome. Am J Clin Pathol. 2011 Apr. 135(4):599-610. [Medline].

  2. Scheinfeld N. Pairing and comparing nine diseases with Degos Disease (Malignant Atrophic Papulosis): an attempt to illustrate our understanding and direct future inquiry. Dermatol Online J. 2009 Jan 15. 15(1):10. [Medline].

  3. Beuran M, Chiotoroiu AL, Morteanu S, Chilie A, Avram M, Rosu O, et al. Köhlmeier-Degos disease (Malignant Atrophic Papulosis): a cause of recurrent multiple intestinal perforations. Chirurgia (Bucur). 2009 Nov-Dec. 6:765-72. [Medline].

  4. High WA, Aranda J, Patel SB, Cockerell CJ, Costner MI. Is Degos' disease a clinical and histological end point rather than a specific disease?. J Am Acad Dermatol. 2004 Jun. 50(6):895-9. [Medline].

  5. Ball E, Newburger A, Ackerman AB. Degos' disease: a distinctive pattern of disease, chiefly of lupus erythematosus, and not a specific disease per se. Am J Dermatopathol. 2003 Aug. 25(4):308-20. [Medline].

  6. Scheinfeld N. Degos' disease is probably a distinct entity: a review of clinical and laboratory evidence. J Am Acad Dermatol. 2005 Feb. 52(2):375-6; author reply 376-8. [Medline].

  7. Wilson J, Walling HW, Stone MS. Benign cutaneous Degos disease in a 16-year-old girl. Pediatr Dermatol. 2007 Jan-Feb. 24(1):18-24. [Medline].

  8. Guhl G, Diaz-Ley B, Delgado Y, Dauden E, Fraga J, Garcia-Diez A. Wegener's granulomatosis: a new entity in the growing differential diagnosis of Degos' disease. Clin Exp Dermatol. 2009 Jul. 34(5):e1-3. [Medline].

  9. Scheinfeld N. Commentary on 'Degos disease: a C5b-9 interferon-alpha;-mediated endotheliopathy syndrome by Magro et al: a reconsideration of Degos disease as hematologic or endothelial genetic disease. Dermatol Online J. 2011 Aug 15. 17(8):6. [Medline].

  10. Passarini B, Balestri R, D'Errico A, Pinna AD, Infusino SD. Lack of recurrence of malignant atrophic papulosis of Degos in multivisceral transplant: insights into possible pathogenesis?. J Am Acad Dermatol. 2011 Aug. 65:e49-50. [Medline].

  11. Meephansan J, Komine M, Hosoda S, et al. Possible involvement of SDF-1/CXCL12 in the pathogenesis of Degos disease. J Am Acad Dermatol. 2013 Jan. 68(1):138-43. [Medline].

  12. al-Smadi RM, Abu-Jamous F, Omeish I. Degos disease in a 24-year-old Jordanian male. East Mediterr Health J. 2000 Jan. 6(1):194-6. [Medline].

  13. Katz SK, Mudd LJ, Roenigk HH Jr. Malignant atrophic papulosis (Degos' disease) involving three generations of a family. J Am Acad Dermatol. 1997 Sep. 37(3 Pt 1):480-4. [Medline].

  14. Lankisch MR, Johst P, Scolapio JS, Fleming CR. Acute abdominal pain as a leading symptom for Degos' disease (malignant atrophic papulosis). Am J Gastroenterol. 1999 Apr. 94(4):1098-9. [Medline].

  15. Jalil J, Shafique M, Rashid Dar N. Dermatological clue to diagnosis of Degos disease in a 2-year-old with obscure chronic abdominal pain. Clin Pediatr (Phila). 2008 Mar. 47(2):180-2. [Medline].

  16. Farrell AM, Moss J, Costello C, Fearfield LA, Woodrow D, Bunker CB. Benign cutaneous Degos' disease. Br J Dermatol. 1998 Oct. 139(4):708-12. [Medline].

  17. Requena L, Farina C, Barat A. Degos disease in a patient with acquired immunodeficiency syndrome. J Am Acad Dermatol. 1998 May. 38(5 Pt 2):852-6. [Medline].

  18. Torrelo A, Sevilla J, Mediero IG, Candelas D, Zambrano A. Malignant atrophic papulosis in an infant. Br J Dermatol. 2002 May. 146(5):916-8. [Medline].

  19. Theodoridis A, Konstantinidou A, Makrantonaki E, Zouboulis CC. Malignant and benign forms of atrophic papulosis (Köhlmeier-Degos disease): systemic involvement determines the prognosis. Br J Dermatol. 2014 Jan. 170(1):110-5. [Medline].

  20. Salomon MI, Mandel EH, Gallo G. Degos' disease associated with a "spontaneous cure" of diabetes. J Am Geriatr Soc. 1971 Nov. 19(11):923-32. [Medline].

  21. Asherson RA, Cervera R. Antiphospholipid syndrome. J Invest Dermatol. 1993 Jan. 100(1):21S-27S. [Medline].

  22. Saglik E, Baykal C, Buyukbabani N, Inanc M. Malignant atrophic papulosis: endocardial involvement and positive anticardiolipin antibodies. J Eur Acad Dermatol Venereol. 2006 May. 20(5):602-3. [Medline].

  23. Fernandez-Flores A, Manjon JA, Mencia J. Diabetes mellitus and Degos disease. Bratisl Lek Listy. 2008. 109(9):414-7. [Medline].

  24. Dyrsen ME, Iwenofu OH, Nuovo G, Magro CM. Parvovirus B19-associated catastrophic endothelialitis with a Degos-like presentation. J Cutan Pathol. 2008 Oct. 35 Suppl 1:20-5. [Medline].

  25. Bogenrieder T, Kuske M, Landthaler M, Stolz W. Benign Degos' disease developing during pregnancy and followed for 10 years. Acta Derm Venereol. 2002. 82(4):284-7. [Medline].

  26. Pati S, Muley SA, Grill MF, Coons S, Walker R. Post-streptococcal vasculopathy with evolution to Degos' disease. J Neurol Sci. 2011 Jan 15. 300(1-2):157-9. [Medline].

  27. Ortiz A, Ceccato F, Albertengo A, Roverano S, Iribas J, Paira S. Degos cutaneous disease with features of connective tissue disease. J Clin Rheumatol. 2010 Apr. 16(3):132-4. [Medline].

  28. Notash AY, Mazoochy H, Mirshams M, Nikoo A. Lethal systemic Degos disease with prominent cardio-pulmonary involvement. Saudi Med J. 2008 Jan. 29(1):133-7. [Medline].

  29. Tan WP, Chio MT, Ng SK. Generalized red papules with gastrointestinal complications. Diagnosis: malignant atrophic papulosis (Degos' disease). Clin Exp Dermatol. 2007 Sep. 32(5):615-6. [Medline].

  30. Egan R, Lessell S. Posterior subcapsular cataract in Degos disease. Am J Ophthalmol. 2000 Jun. 129(6):806-7. [Medline].

  31. Matsuura F, Makino K, Fukushima T, et al. Optic nerve and spinal cord manifestations of malignant atrophic papulosis (Degos disease). J Neurol Neurosurg Psychiatry. 2006 Feb. 77(2):260-2. [Medline].

  32. Sibillat M, Avril MF, Charpentier P, Offret H, Bloch-Michel E. [Malignant atrophic papulosis (Degos' disease): clinical review. Apropos of a case]. J Fr Ophtalmol. 1986. 9(4):299-304. [Medline].

  33. Subbiah P, Wijdicks E, Muenter M, Carter J, Connolly S. Skin lesion with a fatal neurologic outcome (Degos' disease). Neurology. 1996 Mar. 46(3):636-40. [Medline].

  34. Magro CM, Toledo-Garcia A, Pala O, Momtahen S, Shapiro L. Opioid associated intravenous and cutaneous microvascular drug abuse (skin-popping) masquerading as Degos disease (malignant atrophic papulosis) with multiorgan involvement. Dermatol Online J. 2015 Sep 17. 21 (9):[Medline].

  35. Hohwy T, Jensen MG, Tottrup A, Steiniche T, Fogh K. A fatal case of malignant atrophic papulosis (Degos' disease) in a man with factor V Leinden mutation and lupus anticoagulant. Acta Derm Venereol. 2006. 86(3):245-7. [Medline].

  36. Yoshikawa H, Maruta T, Yokoji H, Takamori M, Yachie A, Torii Y. Degos' disease: radiological and immunological aspects. Acta Neurol Scand. 1996 Nov. 94(5):353-6. [Medline].

  37. Amaravadi RR, Tran TM, Altman R, Scheirey CD. Small bowel infarcts in Degos disease. Abdom Imaging. 2008 Mar-Apr. 33(2):196-9. [Medline].

  38. Toledo AE, Shapiro LS, Farrell JF, Magro CM, Polito J. Laparoscopy shows superiority over endoscopy for early detection of malignant atrophic papulosis gastrointestinal complications: a case report and review of literature. BMC Gastroenterol. 2015 Nov 2. 15:156. [Medline].

  39. Scheinfeld N. Malignant atrophic papulosis. Clin Exp Dermatol. 2007 Sep. 32(5):483-7. [Medline].

  40. Zhu KJ, Zhou Q, Lin AH, Lu ZM, Cheng H. The use of intravenous immunoglobulin in cutaneous and recurrent perforating intestinal Degos disease (malignant atrophic papulosis). Br J Dermatol. 2007 Jul. 157(1):206-7. [Medline].

  41. Burgin S, Stone JH, Shenoy-Bhangle AS, McGuone D. Case records of the Massachusetts General Hospital. Case 18-2014. A 32-Year-old man with a rash, myalgia, and weakness. N Engl J Med. 2014 Jun 12. 370(24):2327-37. [Medline].

  42. Shapiro L, Whelan P, Magro C. Case 18-2014: A man with a rash, myalgia, and weakness. N Engl J Med. 2014 Oct 2. 371(14):1361. [Medline].

  43. Magro CM, Wang X, Garrett-Bakelman F, Laurence J, Shapiro LS, DeSancho MT. The effects of Eculizumab on the pathology of malignant atrophic papulosis. Orphanet J Rare Dis. 2013 Nov 26. 8:185. [Medline]. [Full Text].

  44. Shapiro LS, Toledo-Garcia AE, Farrell JF. Effective treatment of malignant atrophic papulosis (Köhlmeier-Degos disease) with treprostinil--early experience. Orphanet J Rare Dis. 2013 Apr 4. 8:52. [Medline]. [Full Text].

  45. Magro C, Shapiro L, Johnson B, Salmon J, Whelan P. Rheumatology Grand Rounds Hospital for Special Surgery (New York City) Degos Disease. Feb 10, 2010. In press.

  46. Theodoridis A, Makrantonaki E, Zouboulis CC. Malignant atrophic papulosis (Kohlmeier-Degos disease) - A review. Orphanet J Rare Dis. 2013 Jan 14. 8(1):10. [Medline].

  47. Shapiro LS, Toledo-Garcia AE, Farrell JF. Effective treatment of malignant atrophic papulosis (Kohlmeier-Degos disease) with treprostinil -- early experience. Orphanet J Rare Dis. 2013 Apr 4. 8(1):52. [Medline].

  48. Ali YN, Hamed M, Azita N. Lethal systemic degos disease with prominent cardio-pulmonary involvement. Indian J Dermatol. 2011 Sep-Oct. 56(5):564-7. [Medline]. [Full Text].

  49. Rajesh R, Basu A, Sistla SC, Jagdish S, Thappa DM, Badhe BA. Degos' disease: acute abdomen with skin rash. Indian J Gastroenterol. 2006 Jul-Aug. 25(4):187. [Medline].

  50. Kim DW, Kang SB, Lee KH, Choe GY, Park SY, Nicholay M. Degos' disease (malignant atrophic papulosis) as a fatal cause of acute abdomen: report of a case. Surg Today. 2008. 38(9):866-70. [Medline].

Four papules of Degos disease located on upper-inner arm in different stages of evolution. Courtesy of David F. Butler, MD.
Papule of Degos disease with central sclerosis and telangiectasia. Courtesy of David F. Butler, MD.
Superficial and mid-dermal perivascular lymphocytic infiltrate with focal vacuolar change at the dermoepidermal junction (hematoxylin and eosin, X100). Courtesy of David F. Butler, MD.
Alcian blue stain for mucin (X100). Courtesy of David F. Butler, MD.
Wedge-shaped area of dermal sclerosis (hematoxylin and eosin, X100). Courtesy of David F. Butler, MD.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.